Attana will pay with about 1.82 million new shares (after its 1:10,000 share consolidation): 80 percent in shares at closing and 20 percent through convertible loans of about SEK 6.7 million. BioNavis’ owners will hold about 64 percent of the combined company, which is why the deal is accounted for as a reverse acquisition.

BioNavis is profitable. In 2025 it reported net sales of SEK 14.1 million and an operating profit of SEK 3.6 million. It has about ten employees and has sold some 300 instruments since 2011. Attana is also raising about SEK 4.5 million in a directed share issue to strengthen its liquidity ahead of closing.

The deal requires approval at an extraordinary general meeting on 17 December and Swedish foreign direct investment clearance. Closing is expected on 22 December.

“Together we create a strong commercial platform with very good conditions to grow and reach profitability faster,” says Arne Nabseth, Chairman of Attana.